Voyager Therapeutics Inc

Price Chart

Risk-Adjusted Performance

Voyager Therapeutics Inc (VYGR) Price Performance

Voyager Therapeutics Inc (VYGR) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $3.92, up 1.82% from the previous close.

Over the past year, VYGR has traded between a low of $2.73 and a high of $5.33. The stock has gained 7.7% over this period. It is currently 26.5% below its 52-week high.

Voyager Therapeutics Inc has a market capitalization of $231.25M.

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.